SG11201609955QA - Nanoencapsulation of antigen-binding molecules - Google Patents

Nanoencapsulation of antigen-binding molecules

Info

Publication number
SG11201609955QA
SG11201609955QA SG11201609955QA SG11201609955QA SG11201609955QA SG 11201609955Q A SG11201609955Q A SG 11201609955QA SG 11201609955Q A SG11201609955Q A SG 11201609955QA SG 11201609955Q A SG11201609955Q A SG 11201609955QA SG 11201609955Q A SG11201609955Q A SG 11201609955QA
Authority
SG
Singapore
Prior art keywords
nanoencapsulation
antigen
binding molecules
molecules
binding
Prior art date
Application number
SG11201609955QA
Other languages
English (en)
Inventor
Anamarija Curic
Jan-Peter Möschwitzer
Original Assignee
Abbvie Deutschland
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Deutschland filed Critical Abbvie Deutschland
Publication of SG11201609955QA publication Critical patent/SG11201609955QA/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/48Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/51Nanocapsules; Nanoparticles
    • A61K9/5107Excipients; Inactive ingredients
    • A61K9/513Organic macromolecular compounds; Dendrimers
    • A61K9/5138Organic macromolecular compounds; Dendrimers obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591Stabilisation, fragmentation
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/44Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Nanotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Optics & Photonics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physical Education & Sports Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
SG11201609955QA 2014-05-30 2015-05-29 Nanoencapsulation of antigen-binding molecules SG11201609955QA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462005163P 2014-05-30 2014-05-30
EP14170537 2014-05-30
PCT/EP2015/061926 WO2015181344A1 (en) 2014-05-30 2015-05-29 Nanoencapsulation of antigen-binding molecules

Publications (1)

Publication Number Publication Date
SG11201609955QA true SG11201609955QA (en) 2016-12-29

Family

ID=50897381

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11201609955QA SG11201609955QA (en) 2014-05-30 2015-05-29 Nanoencapsulation of antigen-binding molecules

Country Status (9)

Country Link
US (2) US20170189345A1 (ja)
EP (1) EP3148516A1 (ja)
JP (1) JP6651507B2 (ja)
CN (1) CN106659694A (ja)
AU (1) AU2015265872B2 (ja)
CA (1) CA2946810A1 (ja)
IL (1) IL248694B (ja)
SG (1) SG11201609955QA (ja)
WO (1) WO2015181344A1 (ja)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MA44323A (fr) * 2015-11-20 2018-09-26 Abbvie Deutschland Nanosphères à surface modifiée encapsulant des molécules liant l'antigène
US11491114B2 (en) * 2016-10-12 2022-11-08 Curioralrx, Llc Formulations for enteric delivery of therapeutic agents
EP4121004A1 (en) 2020-03-20 2023-01-25 University Of Heidelberg Colloidal carrier systems for transfer of agents to a desired site of action

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1815851A1 (en) 2006-02-03 2007-08-08 NanoDel Technologies GmbH Nanoparticles designed for drug delivery
CN101045162B (zh) * 2006-12-11 2011-12-14 台山市友顺化工有限公司 负载药物的聚氰基丙烯酸酯载药纳米粒的制备方法
US20090169635A1 (en) * 2007-12-31 2009-07-02 Alpharx Inc. Pharmaceutical compositions and use thereof
US20110064821A1 (en) * 2008-05-06 2011-03-17 Catchpole Ian Richard Encapsulation of biologically active agents
MX2010012136A (es) * 2008-05-06 2010-12-17 Glaxo Group Ltd Encapsulacion de agentes biologicamente activos.

Also Published As

Publication number Publication date
IL248694B (en) 2021-04-29
IL248694A0 (en) 2017-01-31
AU2015265872B2 (en) 2020-04-09
CN106659694A (zh) 2017-05-10
JP2017524726A (ja) 2017-08-31
CA2946810A1 (en) 2015-12-03
EP3148516A1 (en) 2017-04-05
US20220125737A1 (en) 2022-04-28
WO2015181344A1 (en) 2015-12-03
JP6651507B2 (ja) 2020-02-19
US20170189345A1 (en) 2017-07-06
AU2015265872A1 (en) 2016-11-10

Similar Documents

Publication Publication Date Title
IL283582A (en) ror - gamma modulators
HK1256599A1 (zh) ROR-γ的調節劑
IL252839A0 (en) Treatment of boils
IL251584A0 (en) Dihydropyrrolopyridines ror-gamma inhibitors
IL246902B (en) Dihydropyrrolopyridine ror–gamma inhibitors
ZA201700880B (en) Polymorphs of selinexor
GB201701673D0 (en) Methods of well treatment
SG11201609265RA (en) Characterizing states of subject
IL248697A0 (en) Methods for purifying antibodies
IL247954B1 (en) Immunoglobulin mobilisation
GB201416832D0 (en) Methods of treatment
GB201418395D0 (en) Cyclo-depolymerisation of polybutadiene
IL248694B (en) Nanoencapsulation of antigen binding molecules
FR3024647B1 (fr) Transat de puericulture
GB201412010D0 (en) Treatment of hypertransaminasemia
FR3019594B1 (fr) Section additionnelle de poussee
PL3137475T3 (pl) Oczyszczanie epidaunorubicyny
GB201418773D0 (en) Mechanism of action
GB201417385D0 (en) Pushy
TWM489666U (en) Structure of goggles
GB201416951D0 (en) Method of synthesis
GB201418230D0 (en) Construction of surfaces
FR3024135B1 (fr) Piece de harnachement